This page identifies the research gap for complement system dysregulation as a mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
Background
The Complement System
...
Overview
Mermaid diagram (expand to render)
This page identifies the research gap for complement system dysregulation as a mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
Background
The Complement System
The complement system is a critical component of the innate immune system consisting of >30 proteins that function in a cascade to:
Opsonize pathogens and debris for phagocytosis
Direct cell lysis via membrane attack complex (MAC)
Recruit inflammatory cells
Clear immune complexes
Three activation pathways converge on C3 convertase:
Classical pathway: Initiated by antigen-antibody complexes (C1q)
Lectin pathway: Initiated by mannose-binding lectin
Alternative pathway: Spontaneous C3 activation
Complement in the CNS
The complement system plays important roles in brain development and homeostasis:
Synapse elimination during development (C1q, C3)
Microglial phagocytosis of debris
Protection against pathogens
Tissue repair following injury
Current Knowledge
2024-2026 Research Updates
Recent advances have expanded our understanding of complement in neurodegeneration:
C1q-tau interaction: A 2024 study demonstrated that C1q directly binds to tau oligomers, not just amyloid, suggesting complement may drive tau-mediated neurodegeneration through distinct mechanisms[@zhou2024].
PD complement activation: 2025 research confirmed elevated C1q, C3, and C4 in PD CSF with correlation to disease severity, providing the first robust biomarker evidence in living patients[@ikeda2025].
Therapeutic translation: Complement inhibitors (C1s, C3) are now in Phase 2 trials for AD and ALS, with patient selection biomarkers actively being developed.
Alzheimer's Disease
C1q and Synapse Loss
C1q localizes to synapses in early AD
Prunes synapses via microglial complement receptor 3
Linked to early synaptic dysfunction before amyloid deposition
C3 and Neuroinflammation
C3 elevated in AD brain and CSF
Contributes to chronic neuroinflammation
Astroglial C3 linked to disease severity
Therapeutic Implications
Anti-C1q antibodies in development
C3 inhibition may protect synapses
Complement modulation shows promise in preclinical models
Parkinson's Disease
Complement Activation
C1q and C3 deposition in substantia nigra
Associated with dopaminergic neuron loss
Microglial complement activation
Alpha-synuclein Interaction
C1q binds alpha-synuclein aggregates
May enhance inflammatory clearance
May also promote aggregation
Research Status
Less studied than in AD
Potential therapeutic target under-explored
Amyotrophic Lateral Sclerosis
Complement in Motor Neuron Disease
C1q and C3 associated with motor neuron degeneration
Microglial complement receptor involvement
Contribution to neuromuscular junction elimination
Therapeutic Targeting
Complement inhibitors in clinical trials
C1q as potential biomarker
Research Gaps
Critical Gaps
Mechanistic Understanding
Gap: How does complement dysregulation differ across diseases?
Need: Comparative studies of complement signatures in AD vs PD vs ALS
Priority: High
Biomarker Development
Gap: No validated complement biomarkers for diagnosis or progression
Need: C1q, C3, C4 in CSF as disease markers
Priority: High
Therapeutic Translation
Gap: Unknown optimal timing and patient selection for complement inhibition
Need: Biomarkers predicting treatment response
Priority: High
Microglial Complement Receptors
Gap: CR3 (CD11b/CD18) role in synapse loss unclear